Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1CNS 1

Conditions

Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 2Rectal Neoplasms 1Esthesioneuroblastoma, Olfactory 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cetuximab 4pembrolizumab 3Trastuzumab 3Radiotherapy 3Erlotinib Hydrochloride 3Tomography, X-Ray Computed 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2Docetaxel 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1oblimersen 1nanocis 1mercaptoundecahydrododecaborate 1larotrectinib 1ipatasertib 1fluoromisonidazole 1erythromycin propionate-N-acetylcysteinate 1erdafitinib 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Immunologic Techniques × Head & Neck × Clear all
NCT00896896 2013-04-02

Immunoreactivity to Cetuximab in Cancer Patients

Vanderbilt-Ingram Cancer Center

Completed
538 enrolled
CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Head and Neck Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Colorectal Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡